Buttram Mance E, Kurtz Steven P, Dart Richard C, Margolin Zachary R
Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, FL, USA.
Rocky Mountain Poison & Drug Center, Denver, CO, USA.
Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1083-1086. doi: 10.1002/pds.4230. Epub 2017 May 10.
Recent limited epidemiologic and case reports suggest that gabapentin is being misused, especially among prescription opioid misusers. However, no apparent studies have reported data from law enforcement on the diversion and misuse of gabapentin.
Case report data are drawn from a quarterly survey of prescription drug diversion completed by a national sample of law enforcement and regulatory agencies who engage in drug diversion investigations. Rates of gabapentin diversion per 100 000 population were calculated for each quarter from 2002 through 2015. Qualitative data are drawn from a brief questionnaire completed by a subsample of survey respondents and were organized and presented by theme.
In total, 407 new cases of diverted gabapentin were reported during the time period, with diversion rates steadily increasing from zero cases in the first 2 quarters of 2002 to a high of 0.027 cases per 100 000 population in the fourth quarter of 2015. Qualitative data suggest that gabapentin is being misused in conjunction with prescription opioids and that gabapentin and heroin are being combined and consumed together. Law enforcement reporters found these drug use trends to be contributing to gabapentin diversion.
The recent increase in gabapentin diversion appears to be related to the opioid epidemic, based on law enforcement descriptions of gabapentin being misused in combination with opioids. Yet epidemiological data related to this finding is limited and research conducted among gabapentin misusers is needed to understand this problem in more depth. Greater monitoring of gabapentin abuse and diversion appear warranted.
近期有限的流行病学研究和病例报告表明,加巴喷丁正被滥用,尤其是在处方阿片类药物滥用者中。然而,尚无明显研究报告来自执法部门关于加巴喷丁转移和滥用的数据。
病例报告数据来自一项由参与药物转移调查的执法和监管机构全国样本完成的季度处方药转移调查。计算了2002年至2015年每季度每10万人中加巴喷丁转移的发生率。定性数据来自调查对象子样本填写的简短问卷,并按主题进行组织和呈现。
在此期间共报告了407例新的加巴喷丁转移病例,转移率从2002年前两个季度的零例稳步上升至2015年第四季度的每10万人0.027例的高位。定性数据表明,加巴喷丁与处方阿片类药物一起被滥用,并且加巴喷丁和海洛因被混合并一起使用。执法报告者发现这些药物使用趋势导致了加巴喷丁的转移。
根据执法部门对加巴喷丁与阿片类药物联合滥用的描述,近期加巴喷丁转移的增加似乎与阿片类药物流行有关。然而,与这一发现相关的流行病学数据有限,需要对加巴喷丁滥用者进行研究以更深入地了解这一问题。对加巴喷丁滥用和转移进行更多监测似乎是有必要的。